Bridgeport Hospital

Summary

Bridgeport Hospital is a medical facility located in Bridgeport, Connecticut. This center is recognized for care of Cardiovascular Disease, Breast Cancer, Heart Attack, Stroke, Heart Failure and other specialties. Bridgeport Hospital is involved with conducting 92 clinical trials across 135 conditions. There are 6 research doctors associated with this hospital, such as Edward Tuohy, MD, Adam Schussheim, Alisa Savetamal, MD, and Caroline Loeser, MD.

Top PIs

Clinical Trials running at Bridgeport Hospital

Heart Failure

Type 2 Diabetes

Cardiovascular Disease

Pelvic Organ Prolapse

Gynecologic Surgery

Post Operative Pain Management

Hypertension

High Blood Pressure

Heart Attack

Cardiovascular Risk

BI 690517 + Empagliflozin

for Heart Failure

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.

Recruiting

1 award

Phase 3

2 criteria

Vicadrostat + Empagliflozin

for Heart Failure

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before the study. The purpose of this study is to find out whether a medicine called vicadrostat, in combination with another medicine called empagliflozin, helps people with chronic heart failure. In this study, participants are put into 2 groups randomly. Participants have an equal chance of being in either group. One group takes vicadrostat/empagliflozin tablets, and the other group takes placebo/empagliflozin tablets. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take the study medicines as tablets once a day for between 1 and about 3.5 years. During this time, they can continue their regular treatment for heart failure. Participants can stay in the study as long as they benefit from treatment and can tolerate it, for a maximum of about 3.5 years. During this time, they visit the study site regularly. The exact number of visits is different for each participant, depending on how long they stay in the study. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The doctors document when participants experience worsening of their heart failure symptoms, must go to hospital due to heart failure, or die during the study. The time until these events are observed is compared between the treatment groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Recruiting

1 award

Phase 3

1 criteria

Ziltivekimab

for Heart Failure

This trial is testing ziltivekimab to see if it can help people with heart failure and inflammation by reducing inflammation and improving heart function.

Recruiting

1 award

Phase 3

7 criteria